Douglas J. Manion

Insider Reports History

Entity
Individual
Location
C/O Aclaris Therapeutics, Inc., 701 Lee Road, Suite 103, Wayne, PA
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Douglas J. Manion:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Aclaris Therapeutics, Inc. Pres and CEO, Director Restricted Stock Units 81K $85.1K $1.05 Jan 1, 2024 Direct
Aclaris Therapeutics, Inc. Pres and CEO, Director Common Stock 41.8K $43.9K $1.05 Jan 1, 2024 Direct
ARENA PHARMACEUTICALS INC EVP Research & Development Common Stock 0 $98.51 Mar 11, 2022 Direct
ARENA PHARMACEUTICALS INC EVP Research & Development Employee Performance Restricted Stock Unit 0 Mar 11, 2022 Direct
ARENA PHARMACEUTICALS INC EVP Research & Development Employee Stock Option (right to buy) 0 Mar 11, 2022 Direct

Insider Reports Filed by Douglas J. Manion

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ACRS Aclaris Therapeutics, Inc. Jan 1, 2024 3 -$9.58K 4 Jan 3, 2024 Pres and CEO, Director
ACRS Aclaris Therapeutics, Inc. Aug 1, 2023 3 -$43.5K 4 Aug 3, 2023 Pres and CEO, Director
ACRS Aclaris Therapeutics, Inc. Mar 17, 2023 1 $49.5K 4 Mar 17, 2023 Pres and CEO, Director
ACRS Aclaris Therapeutics, Inc. Mar 9, 2023 1 $50.3K 4 Mar 9, 2023 Pres and CEO, Director
ACRS Aclaris Therapeutics, Inc. Feb 1, 2023 2 $0 4 Feb 3, 2023 Pres and CEO, Director
ACRS Aclaris Therapeutics, Inc. Aug 1, 2022 2 $0 4 Aug 2, 2022 Pres and COO
ACRS Aclaris Therapeutics, Inc. Aug 1, 2022 0 $0 3 Aug 2, 2022 Pres and COO
ARNA ARENA PHARMACEUTICALS INC Mar 11, 2022 4 $0 4 Mar 11, 2022 EVP Research & Development
ARNA ARENA PHARMACEUTICALS INC Jan 3, 2022 1 $0 4 Jan 5, 2022 EVP Research & Development
ARNA ARENA PHARMACEUTICALS INC Aug 15, 2021 3 $0 4 Aug 17, 2021 EVP Research & Development
ARNA ARENA PHARMACEUTICALS INC Jul 19, 2021 0 $0 3 Jul 29, 2021 EVP Research & Development